Roche's headquarters in Basel, Switzerland (Kyle LaHucik for Endpoints News)

Roche ditch­es fi­nal PhI­II for can­cer hope­ful, re­ports set­back for key drug in $1.4B buy­out

Over the past few years, Roche has re­leased news about its AKT in­hibitor ipatasert­ib in drips — most of them neg­a­tive. The drug yield­ed mixed da­ta in a key prostate can­cer tri­al, Phase III flops in triple-neg­a­tive breast can­cer forced the phar­ma gi­ant to pull the plug there, and in mid-2022 Roche trimmed two more ear­ly-stage in­di­ca­tions in prostate can­cer af­ter com­plet­ing the tri­als.

Now, the last piece of the pro­gram is gone.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.